The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), David L. Grinblatt(NorthShore University HealthSystem), E. Dawn Flick, Pavel Kiselev, Charles M. Farber(Morristown Medical Center), Matthew S. Davids(Dana-Farber Cancer Institute), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Arlene S. Swern, Chadi Nabhan(University of Chicago), Kristen Sullivan, Neil E. Kay(Mayo Clinic), Sarah M. Gressett Ussery(Karyopharm Therapeutics (United States)), Mecide Gharibo(Bristol-Myers Squibb (United States))
Cited by 19
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k